Oral MS drug Gilenya slows brain inflammation
Oral MS drug Gilenya slows brain inflammation
The multiple sclerosis medication fingolimod (Gilenya) led to "rapid and sustained" reductions in MRI-documented inflammatory lesion activity, researchers reported.
In a two-year randomized trial, the medication also slowed the rate of brain volume loss compared with placebo, according to Ernst-Wilhelm Radue, MD, of University Hospital Basel in Basel, Switzerland, and colleagues.
Changes in lesion volume over time also favoured the medication rather than placebo, Radue and colleagues reported online in Archives of Neurology.
Combined with previously reported improvements in relapse rates and disability progression, the findings suggest that the drug -- a sphingosine 1–phosphate receptor (S1PR) modulator -- has a "positive impact on long-term disease evolution," the researchers argued....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1323 Views
-
Last post by NHE
-
- 0 Replies
- 1850 Views
-
Last post by frodo
-
- 0 Replies
- 2278 Views
-
Last post by frodo
-
- 0 Replies
- 741 Views
-
Last post by NHE
-
- 0 Replies
- 1170 Views
-
Last post by frodo
-
- 2 Replies
- 2922 Views
-
Last post by frodo
-
- 6 Replies
- 1636 Views
-
Last post by DIM
-
- 0 Replies
- 1236 Views
-
Last post by frodo
-
- 1 Replies
- 1019 Views
-
Last post by Petr75